Connection

Hubert Schrezenmeier to Hemolysis

Back to Details
This is a "connection" page, showing publications Hubert Schrezenmeier has written about Hemolysis.
Hubert Schrezenmeier
Connection Strength
0.244
Hemolysis
  1. Complement activation by human red blood cell antibodies: hemolytic potential of antibodies and efficacy of complement inhibitors assessed by a sensitive flow cytometric assay. Transfusion. 2018 12; 58(12):2992-3002.
    View in: PubMed
    Score: 0.153
  2. Ravulizumab (ALXN1210) in patients with paroxysmal nocturnal hemoglobinuria: results of 2 phase 1b/2 studies. Blood Adv. 2018 09 11; 2(17):2176-2185.
    View in: PubMed
    Score: 0.038
  3. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. Blood. 2017 02 23; 129(8):970-980.
    View in: PubMed
    Score: 0.034
  4. The management of paroxysmal nocturnal hemoglobinuria: recent advances in diagnosis and treatment and new hope for patients. Semin Hematol. 2009 Jan; 46(1 Suppl 1):S1-S16.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.